Novastan®(brand of argatroban): a small-molecule, direct thrombin inhibitor MJ Hursting, KL Alford, JP Becker, RL Brooks, JL Joffrion, ... Seminars in thrombosis and hemostasis 23 (06), 503-516, 1997 | 177 | 1997 |
Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo … P Tran, P Skolnick, P Czobor, NY Huang, M Bradshaw, A McKinney, ... Journal of psychiatric research 46 (1), 64-71, 2012 | 92 | 2012 |
Sustained release formulation of naltrexone AA McKinney, GD Tollefson, R Soltero, TE Dunzo US Patent 8,916,195, 2014 | 75 | 2014 |
Layered pharmaceutical formulations A McKinney, G Tollefson, E Weber, R Soltero US Patent 8,088,786, 2012 | 67 | 2012 |
Methods for administering weight loss medications A McKinney, G Tollefson, E Weber, R Soltero US Patent 8,722,085, 2014 | 55 | 2014 |
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats NM Wallingford, P Sinnayah, FP Bymaster, KM Gadde, RK Krishnan, ... Neuropsychopharmacology 33 (12), 2922-2933, 2008 | 49 | 2008 |
Compositions and methods for reducing food cravings A McKinney, G Tollefson, M Cowley US Patent App. 11/602,813, 2007 | 47 | 2007 |
Compositions of an anticonvulsant and methods of using the same for reversing weight gain A McKinney, G Tollefson, M Cowley US Patent App. 11/622,363, 2007 | 43 | 2007 |
Compositions and methods for increasing insulin sensitivity MA Cowley, AA McKinney, G Tollefson US Patent 8,815,889, 2014 | 42 | 2014 |
Methods for administering weight loss medications AA McKinney, G Tollefson, E Weber, R Soltero US Patent 9,125,868, 2015 | 41 | 2015 |
Methods for administering weight loss medications A McKinney, G Tollefson, E Weber, R Soltero US Patent App. 11/937,367, 2008 | 38 | 2008 |
State-of-the-Art Review: The Preclinical and Clinical Pharmacology of Novastan (Argatroban): A Small-Molecule, Direct Thrombin Inhibitor RP Schwarz Jr, JCP Becker, RL Brooks, MJ Hursting, JL Joffrion, ... Clinical and Applied Thrombosis/Hemostasis 3 (1), 1-15, 1997 | 37 | 1997 |
Preparation and Use of (+)-1-(3, 4-Dichlorophenyl)-3-Azabicyclo [3.1. 0] Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters AA McKINNEY, F Bymaster, W Piskorski US Patent App. 13/310,694, 2012 | 24 | 2012 |
Compositions for affecting weight loss G Tollefson, A McKinney, M Higgin, J McCall US Patent App. 11/492,685, 2007 | 24 | 2007 |
Layered pharmaceutical formulations A McKinney, G Tollefson, E Weber, R Soltero US Patent 8,318,788, 2012 | 21 | 2012 |
Sustained-release formulation of zonisamide A McKinney, G Tollefson, S Yau, R Vladyka, R Soltero US Patent App. 11/563,618, 2007 | 20 | 2007 |
Compositions and methods for reducing food cravings AA McKinney, G Tollefson, MA Cowley US Patent App. 12/903,131, 2011 | 19 | 2011 |
Safety and efficacy of centanafadine sustained-release in adults with attention-deficit hyperactivity disorder: results of phase 2 studies SB Wigal, T Wigal, M Hobart, JJ Madera, RA Baker, E Kohegyi, ... Neuropsychiatric Disease and Treatment, 1411-1426, 2020 | 17 | 2020 |
Use Of (1R, 5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo [3.1. 0] Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters AA McKINNEY, F Bymaster US Patent App. 13/907,921, 2014 | 13 | 2014 |
Sustained release formulation of naltrexone AA McKinney, GD Tollefson, R Soltero, TE Dunzo US Patent 9,107,837, 2015 | 12 | 2015 |